On November 4, 2026 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, reported that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will summarize updated 12-month follow-up data from the Phase 2b CLOVER WaM clinical trial, including new analyses exhibiting a significantly longer duration of response in patients who received iopofosine I 131 after only two prior lines of therapy compared with more heavily pretreated patients. These findings strengthen the clinical rationale for iopofosine I 131 in relapsed or refractory WM and support its potential evaluation in earlier treatment settings, where substantial unmet need remains. The company will also present, for the first time, the detailed design of its Phase 3 confirmatory study in WM patients previously treated with a Bruton tyrosine kinase inhibitor (BTKi). Site activation and other start-up activities are underway for the company’s global Phase 3 confirmatory study, with first patient dosing anticipated in the first quarter of 2027.

"The new data being presented at ASH (Free ASH Whitepaper) further strengthen the clinical profile of iopofosine I 131, underscoring its potential to deliver durable responses and address a significant unmet need in relapsed or refractory Waldenström macroglobulinemia," said Jarrod Longcor, chief operating officer of Cellectar Biosciences. "These updated CLOVER WaM results demonstrate durable responses in heavily pretreated patients, while new analyses suggest the potential for even greater durability of benefit when iopofosine I 131 is used in earlier lines of therapy. These findings reinforce our confidence in its clinical potential as we advance our registrational strategy. In parallel, we are targeting the first half of 2027 for an FDA submission seeking accelerated approval. These planned milestones define a clear path forward as we work to bring iopofosine I 131 to patients with limited treatment options."

Details of the upcoming presentations are as follows:

Title: "An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated with a Bruton Tyrosine Kinase Inhibitor: A Trial-in-Progress"
Session #: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Date/Time: December 12, 2026, 5:30:00 PM – 7:30:00 PM
Location: MCCNO – Hall F
Publication Number: 1799
Presenter: Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences

Title: "Duration of Response to Iopofosine I 131 in Patients with Relapsed/Refractory Waldenström Macroglobulinemia by Prior Lines of Therapy: Results from the Pivotal Phase 2b CLOVER WaM Study"
Session #: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Date/Time: December 12, 2026, 5:30:00 PM – 7:30:00 PM
Location: MCCNO – Hall F
Publication Number: 1790
Presenter: Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences

Title: "Iopofosine I 131 in Waldenström macroglobulinemia: 12-month follow up data from the CLOVER-WaM trial"
Session #: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III I
Date/Time: December 14, 2026, 6:00:00 PM – 8:00:00 PM
Location: MCCNO – Hall F
Publication Number: 5325
Presenter: Sikander Ailawadhi, MD, Professor of Medicine, Mayo Clinic

(Press release, Cellectar Biosciences, NOV 4, 2026, View Source [SID1234674160])